B. Riley Financial Lowers Altimmune (NASDAQ:ALT) Price Target to $13.00

Altimmune (NASDAQ:ALT) had its target price reduced by B. Riley Financial from $18.00 to $13.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. B. Riley Financial’s price target indicates a potential upside of 267.23% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research note on Thursday. Citizens Jmp reduced their price target on Altimmune from $15.00 to $14.00 and set a “market outperform” rating on the stock in a report on Friday, November 7th. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Wednesday, November 12th. Finally, Barclays assumed coverage on shares of Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective for the company. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $16.60.

Altimmune Stock Up 0.9%

Shares of NASDAQ ALT opened at $3.54 on Friday. The stock has a market cap of $399.42 million, a PE ratio of -3.50 and a beta of 0.13. The company has a current ratio of 17.18, a quick ratio of 17.18 and a debt-to-equity ratio of 0.08. Altimmune has a 12-month low of $2.90 and a 12-month high of $7.73. The company has a 50-day moving average of $4.48 and a 200 day moving average of $4.29.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). The business had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. Altimmune had a negative return on equity of 54.03% and a negative net margin of 214,860.98%. As a group, sell-side analysts predict that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Buying and Selling at Altimmune

In other Altimmune news, Director Jerome Benedict Durso bought 12,500 shares of Altimmune stock in a transaction on Monday, December 22nd. The shares were bought at an average price of $4.13 per share, for a total transaction of $51,625.00. Following the completion of the transaction, the director directly owned 12,500 shares of the company’s stock, valued at $51,625. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director John Gill purchased 12,500 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The stock was acquired at an average cost of $4.10 per share, for a total transaction of $51,250.00. Following the purchase, the director owned 12,500 shares in the company, valued at approximately $51,250. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have acquired 30,527 shares of company stock valued at $125,278. 4.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Arax Advisory Partners boosted its stake in Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock worth $29,000 after buying an additional 4,076 shares during the period. SBI Securities Co. Ltd. lifted its holdings in shares of Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Altimmune in the 4th quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new position in shares of Altimmune during the 3rd quarter worth approximately $38,000. Finally, CreativeOne Wealth LLC acquired a new stake in Altimmune in the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Key Altimmune News

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: Company advanced pemvidutide development — management reiterated plans to initiate a Phase 3 MASH trial in 2026, pemvidutide received FDA Breakthrough Therapy designation for MASH, and RECLAIM Phase 2 topline data in AUD is expected in 3Q 2026. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Balance sheet strengthened — company reported about $274M in cash, cash equivalents and short-term investments at year-end and completed a $75M registered direct offering in January, supporting clinical programs and runway. Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates
• Positive Sentiment: Company outlined a large, 1,800‑patient Phase III MASH design and signaled cash runway into 2028 as pemvidutide advances — this reduces near-term execution risk for the lead program. Altimmune outlines 1,800-patient Phase III MASH trial and signals cash runway into 2028
• Neutral Sentiment: B. Riley cut its price target from $18 to $13 but kept a Buy rating — the new target still implies meaningful upside vs. current levels, though it reduces analyst enthusiasm relative to prior coverage. Benzinga
• Neutral Sentiment: Earnings call and transcripts are available for review — useful for investors who want management’s commentary on timelines, trial designs and cash runway. Altimmune Q4 2025 Earnings Call Transcript (Seeking Alpha)
• Neutral Sentiment: Reported short-interest notes appear to show anomalous/zero values in public data feeds and are not a reliable signal at this time.
• Negative Sentiment: Q4 earnings missed estimates — EPS of ($0.27) vs. consensus ($0.25) and immaterial GAAP revenue ($0.03M); very large negative margins and negative ROE highlight ongoing R&D spending and lack of commercial revenue. Altimmune stock edges down on fourth quarter earnings miss

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.